Pfizer looks to consolidate in Cambridge; Nuron licenses Alzheimer's vaccine; Raptor tries for early regulatory win;

@FierceBiotech: Wellcome Trust joins chorus calling for free online access to medical research. Story | Follow @FierceBiotech

@JohnCFierce: Affymax collects a $50M milestone check for peginesatide approval. Release | Follow @JohnCFierce

@RyanMFierce: GAVI scores price cuts for $GSK and $MRK rotavirus shots. News | Follow @RyanMFierce

> Pfizer ($PFE) has put Wyeth's old HQ building in Cambridge, MA, up for sale, hoping it can relocate the workers there to its facilities in Kendall Square. Story

> Nuron Biotech has licensed an experimental Alzheimer's vaccine from Vitruvian. Financial details were not disclosed. Report

> Just 6 years after it was founded, Raptor Pharmaceutical ($RPTP) is hoping it can gain its first drug approval. Story

Pharma News

@FiercePharma: Teva's newly confirmed hold on the Provigil market makes its forecast look 'conservative,' analyst tells Bloomberg. More | Follow @FiercePharma

> Predictably, Icahn sues Amylin to open proxy fight. News

> J&J looks for workaround to ease Doxil shortage. Item

Medical Devices News

@FierceMedDev: FDA combats criticisms over speed with ESRD pathway. Story | Follow @FierceMedDev

> Medtronic backs Hauser's findings on Riata leads. More

> Medtronic starts Jacksonville, FL, expansion. Item

Research News

> Tarantula venom, baking soda explored to fight breast cancer. Item

> Salk scientists eye 2 new targets against Type 2 diabetes. More

> Novel drug blasts leukemia in zebra fish. Piece

> Three studies back notion of autism erupting from genetic mutations. Article

> Novartis drug discovery repairs arthritic knees in mice. Story

Manufacturing News

> FDA builds program for outsourcing foreign plant inspections. Item

> New plant pushes Ranbaxy Lipitor production to global lead. Article

> FDA disbars 4 quality control execs from defunct Able Laboratories. More

> India considers track and trace system to combat counterfeiters. News

And Finally… A new study suggests those omega-3 supplements don't do anything to improve cardiovascular health. Story

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.